Cover image not available

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

National Institute for Health and Clinical Excellence

Publication Data

Title Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and Clinical Excellence
Publication date 2009
Publication location London
Language English

Descriptive Notes

Issue date: August 2009.
"The guidance was developed using the NICE multiple technology appraisal process."
Publisher's number: N1983.

Topics

Renal cell carcinoma :: Chemotherapy

Catalogue Data

OBNB ID GBB586047
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99461061

ISBD

P1053 1 online resource (2 unnumbered pages).
P1042 Includes bibliographical references.

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence in 2009. Publication and catalogue information, links to buy online and reader comments.